Lisata Therapeutics, Inc. - Common Stock (LSTA)
0.9901
+0.0001 (0.01%)
NASDAQ · Last Trade: Nov 6th, 12:40 PM EST
News & Press Releases
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
SOUTH SAN FRANCISCO, Calif. and LIBERTY CORNER, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that management will participate in the following investor conferences:
By Lisata Therapeutics, Inc. · Via GlobeNewswire · November 5, 2026
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 14, 2026
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
LIBERTY CORNER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company, today announced that the United States Patent and Trademark Office (“USPTO”) has granted a new Method of Use patent for certepetide [U.S. Patent No. 12,751,991] for the treatment of pancreatic cancer and other solid tumors, expiring May 2041.
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 8, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
Trial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
By Lisata Therapeutics, Inc. · Via GlobeNewswire · October 5, 2026
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · October 4, 2026
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function
By Lisata Therapeutics, Inc. · Via GlobeNewswire · September 24, 2026
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases
By Lisata Therapeutics, Inc. · Via GlobeNewswire · September 17, 2026
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders
By Lisata Therapeutics, Inc. · Via GlobeNewswire · August 4, 2026
These stocks are moving in today's after hours sessionchartmill.com
Via Chartmill · July 28, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · July 21, 2026
The market is filled with gapping stocks in Tuesday's session.chartmill.com
Via Chartmill · July 21, 2026
Wondering what's happening in today's pre-market session?chartmill.com
Via Chartmill · July 21, 2026
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones
By Lisata Therapeutics, Inc. · Via GlobeNewswire · June 10, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
BALA CYNWYD, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · May 14, 2026
Halper Sadeh LLC is Investigating Whether NSA, LSTA, TALK are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · May 12, 2026
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · May 5, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
BALA CYNWYD, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · May 5, 2026
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · May 4, 2026
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
By Halper Sadeh LLC · Via GlobeNewswire · March 10, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share
By Lisata Therapeutics, Inc. · Via GlobeNewswire · March 6, 2026
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
Shareholders should contact the firm as there may be limited time to enforce your rights
By Halper Sadeh LLC · Via GlobeNewswire · February 2, 2026
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · February 2, 2026
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights
By Halper Sadeh LLC · Via GlobeNewswire · January 29, 2026
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights.
By Halper Sadeh LLC · Via GlobeNewswire · January 27, 2026